Answers are grounded in this paper and cite their sources.
Better and better: The glycosidic prodrug (+)-1, which is based on duocarmycin antibiotics, was synthesized for selective cancer therapy. The drug was developed within the context of “antibody-directed enzyme prodrug therapy” (ADEPT). As a result of its outstanding QIC50 values, its excellent solubility, and easy synthesis it exceeds all other prodrugs produced to date. QIC50=comparative toxicity value between the prodrug and the drug.
No takes yet. Share an insight, caveat, or question.
Tietze et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: